Terms: = Cervical cancer AND EP300, ENSG00000100393, 2033, RP1-85F18_1, p300 AND Treatment
12 results:
1. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
Li J; Xue X; Zhang Y; Ding F; Wu W; Liu C; Xu Y; Chen H; Ou Q; Shao Y; Li X; Wu F; Wu X
Gynecol Oncol; 2023 Aug; 175():133-141. PubMed ID: 37356314
[TBL] [Abstract] [Full Text] [Related]
2. PHLDA1 is a P53 target gene involved in P53-mediated cell apoptosis.
Song X; Zhou L; Yang W; Li X; Ma J; Qi K; Liang R; Li M; Xie L; Su T; Huang D; Liang B
Mol Cell Biochem; 2024 Mar; 479(3):653-664. PubMed ID: 37155089
[TBL] [Abstract] [Full Text] [Related]
3. ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing.
Machida H; Matsuo K; Tanaka M; Kitatani K; Takase A; Yokoyama K; Kajiwara H; Yasaka M; Ikeda M; Yoshida H; Hirasawa T; Mikami M
Gynecol Oncol; 2023 Apr; 171():59-66. PubMed ID: 36804622
[TBL] [Abstract] [Full Text] [Related]
4. An integrative approach toward identification and analysis of therapeutic targets involved in HPV pathogenesis with a focus on carcinomas.
Gupta AK; Kumar M
Cancer Biomark; 2023; 36(1):31-52. PubMed ID: 36245368
[TBL] [Abstract] [Full Text] [Related]
5. Knockdown of MIR9‑3HG inhibits proliferation and promotes apoptosis of cervical cancer cells by miR‑498 via ep300.
Li F; Liang Y; Ying P
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34468010
[TBL] [Abstract] [Full Text] [Related]
6. Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible.
Lee TH; Song C; Kim IA; Kim JS; Kim YB; Kim K; No JH; Suh DH; Chung JB; Eom KY
Radiat Oncol; 2021 Aug; 16(1):148. PubMed ID: 34384450
[TBL] [Abstract] [Full Text] [Related]
7. p300-Catalyzed Lysine Crotonylation Promotes the Proliferation, Invasion, and Migration of HeLa Cells via Heterogeneous Nuclear Ribonucleoprotein A1.
Han X; Xiang X; Yang H; Zhang H; Liang S; Wei J; Yu J
Anal Cell Pathol (Amst); 2020; 2020():5632342. PubMed ID: 33457194
[TBL] [Abstract] [Full Text] [Related]
8. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
Yoshimoto Y; Sasaki Y; Murata K; Noda SE; Miyasaka Y; Hamamoto J; Furuya M; Hirato J; Suzuki Y; Ohno T; Tokino T; Oike T; Nakano T
Gynecol Oncol; 2020 Nov; 159(2):546-553. PubMed ID: 32951893
[TBL] [Abstract] [Full Text] [Related]
9. Management and outcome of cervical cancer diagnosed in pregnancy.
Bigelow CA; Horowitz NS; Goodman A; Growdon WB; Del Carmen M; Kaimal AJ
Am J Obstet Gynecol; 2017 Mar; 216(3):276.e1-276.e6. PubMed ID: 27810552
[TBL] [Abstract] [Full Text] [Related]
10. Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis.
Wu ZZ; Sun NK; Chao CC
J Cell Physiol; 2011 Sep; 226(9):2415-28. PubMed ID: 21660965
[TBL] [Abstract] [Full Text] [Related]
11. Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer.
Chen CC; Lin JC; Jan JS; Ho SC; Wang L
Gynecol Oncol; 2011 Jul; 122(1):9-13. PubMed ID: 21514629
[TBL] [Abstract] [Full Text] [Related]
12. Inhibition of human papillomavirus-16 long control region activity by interferon-gamma overcome by p300 overexpression.
Fontaine V; van der Meijden E; ter Schegget J
Mol Carcinog; 2001 May; 31(1):27-36. PubMed ID: 11398195
[TBL] [Abstract] [Full Text] [Related]
